London partner Matthew Hall co-hosted the March 30 episode of the Our Curious Amalgam podcast on the topic “What Is the Competitive Drug Price? Understanding Drug Pricing and Competition in Europe.”
The pricing of pharmaceuticals, and in particular whether prices are “too high” or “excessive”, is a contentious topic in the EU, as elsewhere. What is “excessive” in this context and what other antitrust arguments are used in this key sector? Paul Csiszar, Director, European Commission, DG Competition joins Matthew Hall and others to discuss recent cases and policy directions, including several cases based on allegations of abuse of dominance by pharmaceutical companies. Listen to this episode to learn more about how EU competition/antitrust law can be one part of the toolbox available to investigate and deal with the issue of excessive pricing in pharmaceuticals.
To listen to the podcast, click here.